Skip to content

US · CTSO · MEDICAL - DEVICES

Cytosorbents Corporation (CTSO) intrinsic value and stock valuation

$4.16as of 2026-11-21 · Mkt cap 22.62M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cytosorbents Corporation DCF and intrinsic value

InvestorsCraft values CTSO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CTSO’s statements →

Cytosorbents Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Princeton, NJ 08540 cytosorbents.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$37.1M-1.2% 5y CAGRd
20112025
Net income
-$-8.2M
20112025
Free cash flow
-$-12.54M
20112025
Total equity
$5.9M-40.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$37.1M$35.6M$31.1M$34.7M$40.1M
Operating income-$-14.24M-$-16.45M-$-31.95M-$-31.52M-$-22.74M
Net income-$-8.2M-$-20.72M-$-29.25M-$-32.81M-$-24.56M
EPSd-$-131.77K-$-380.67K-$-654.95K-$-753.04K-$-566.42K
Operating cash flow-$-12.38M-$-14.43M-$-21.66M-$-28.23M-$-14.01M
Capital expenditure-$-160K-$-280K-$-940K-$-6.46M-$-4.28M
Free cash flow-$-12.54M-$-14.71M-$-22.59M-$-34.69M-$-18.29M
Total assets$44.2M$47.4M$53.3M$63.2M$89.5M
Total debt$29.1M$26.9M$18.3M$18.3M$13.8M
Net debt$22.9M$23.6M$4.18M-$-3.89M-$-38.32M
Total equity$5.9M$11.1M$23.3M$35.4M$62.6M
Cash and short-term investments$6.25M$3.28M$14.1M$22.1M$52.1M
Income statement
20252024202320222021
Revenue$37.1M$35.6M$31.1M$34.7M$40.1M
Cost of revenue$10.6M$10.7M$9.13M$14M$11.1M
Gross profit$26.5M$24.9M$22M$20.7M$29.1M
Research and development expenses$5.08M$7.61M$15.6M$15.1M$16.4M
Selling, general and administrative expenses$35.7M$33.7M$38.3M$2.79M$38.5M
Other expenses$0.00$0.00$0.00$34.3M-$-3.06M
Operating expenses$40.7M$41.3M$53.9M$52.3M$51.8M
Cost and expenses$51.3M$52.1M$63M$66.2M$62.9M
Interest income$0.00$0.00$0.00$130K$30K
Interest expense$2.61M$1.4M$160K$0.00$0.00
Depreciation and amortization$1.63M$1.74M$2.02M$880K$1.13M
Ebitda-$-4.36M-$-19.27M-$-27.88M-$-30M-$-24.17M
Operating income-$-14.24M-$-16.45M-$-31.95M-$-31.52M-$-22.74M
Total other income/expenses, net$5.64M-$-5.96M$1.89M-$-2.38M-$-2.55M
Income before tax-$-8.6M-$-22.41M-$-30.06M-$-33.91M-$-25.29M
Income tax expense-$-400K-$-1.69M-$-810K-$-1.09M-$-740K
Net income-$-8.2M-$-20.72M-$-29.25M-$-32.81M-$-24.56M
Weighted average shares outstanding$62.2M$54.4M$44.7M$43.6M$43.4M
Weighted average diluted shares outstanding$62.2M$54.4M$44.7M$43.6M$43.4M
Balance sheet
20252024202320222021
Cash and short-term investments$6.25M$3.28M$14.1M$22.1M$52.1M
Net receivables$7.55M$7.32M$6.06M$5.66M$4.52M
Inventory$5.28M$2.73M$3.68M$3.46M$4.77M
Total current assets$20.6M$21.6M$25.7M$33.8M$64.3M
Property, plant and equipment, net$18.8M$20.5M$22.1M$23.4M$18.6M
Goodwill and intangible assets$3.23M$3.75M$3.91M$4.39M$4.7M
Long-term investments$1.52M$0.00$1.48M$1.73M$1.94M
Total non-current assets$23.6M$25.8M$27.6M$29.5M$25.2M
Total assets$44.2M$47.4M$53.3M$63.2M$89.5M
Accounts payable$2.87M$3.34M$3.8M$1.66M$2.81M
Short-term debt$540K$450K$2.87M$110K$570K
Deferred revenue$330K$420K$1.38M$1.52M$1.95M
Total current liabilities$9.71M$9.82M$14.6M$9.71M$13.7M
Long-term debt$28.6M$26.4M$15.4M$18.1M$13.3M
Deferred revenue, non-current$0.00$0.00-$-3.71M$0.00$0.00
Total non-current liabilities$28.6M$26.4M$15.4M$18.1M$13.3M
Capital lease obligations$12.4M$12.9M$13.3M$13.1M$13.3M
Total liabilities$38.3M$36.3M$30M$27.9M$26.9M
Common stock$60K$50K$50K$40K$40K
Retained earnings-$-312.21M-$-304.01M-$-282.51M-$-254M-$-221.19M
Accumulated other comprehensive income (loss)-$-2.98M$4.25M$530K$2.33M$530K
Total equity$5.9M$11.1M$23.3M$35.4M$62.6M
Total investments$1.52M$0.00$1.48M$1.73M$1.94M
Total debt$29.1M$26.9M$18.3M$18.3M$13.8M
Net debt$22.9M$23.6M$4.18M-$-3.89M-$-38.32M
Cash flow statement
20252024202320222021
Net income-$-8.2M-$-20.72M-$-28.51M-$-32.81M-$-24.56M
Depreciation and amortization$950K$1.75M$2.03M$1.13M$1.13M
Stock-based compensation$2.77M$3.76M$3.7M$3.8M$6.2M
Change in working capital-$-1.03M-$-4.38M$2.36M-$-3.56M$640K
Accounts receivable$420K-$-1.72M-$-250K-$-1.29M$420K
Inventory-$-2.54M$500K-$-120K$950K-$-2.35M
Accounts payable-$-710K-$-1.81M$1.62M-$-3.25M$2.43M
Net cash provided by operating activities-$-12.38M-$-14.43M-$-21.66M-$-28.23M-$-14.01M
Investments in property, plant and equipment-$-160K-$-670K-$-940K-$-6.46M-$-4.28M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-410K-$-670K-$-940K-$-6.46M-$-4.28M
Common stock issued$6.83M$180K$14.3M-$-40K$720K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$9.31M$9.33M$14.5M$4.96M$720K
Net change in cash-$-1.99M-$-5.85M-$-8.22M-$-29.99M-$-17.6M
Cash at end of period$7.77M$9.76M$15.6M$23.8M$53.8M
Operating cash flow-$-12.38M-$-14.43M-$-21.66M-$-28.23M-$-14.01M
Capital expenditure-$-160K-$-280K-$-940K-$-6.46M-$-4.28M
Free cash flow-$-12.54M-$-14.71M-$-22.59M-$-34.69M-$-18.29M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cytosorbents Corporation

        Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.

        CEO
        Phillip Chan
        Employees
        129
        Beta
        1.39

        Explore

        Frequently asked questions

        What is the intrinsic value of Cytosorbents Corporation (CTSO)?

        Cytosorbents Corporation (CTSO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CTSO undervalued?

        CTSO trades at a price of $4.16 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.